(Q37765561)

English

Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities

scientific article published on July 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1 reference

Europe PubMed Central

Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

George J Kontoghiorghes

1

object named as

George J Kontoghiorghes

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

language of work or name

0 references

publication date

1 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Expert Opinion on Drug Safety

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

633-641

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Effects of ICL670 (deferasirox) on cardiac iron concentrations

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Fanconi syndrome due to deferasirox.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine)

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

High doses of deferiprone may be associated with cerebellar syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

DESFERRIOXAMINE AND SYSTEMIC YERSINIOSIS

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.497138

21 January 2018

Identifiers

10.1517/14740338.2010.497138

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37765561&oldid=2121463399"